Award Number: DAMD17-00-1-0062

TITLE: Phase IIA Chemopreventative Study of Selenium in Persons

at Risk for Lung Cancer

PRINCIPAL INVESTIGATOR: Jeffrey P. Krischer, Ph.D.

CONTRACTING ORGANIZATION: University of South Florida

Tampa, Florida 33620-7900

REPORT DATE: December 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		3. REPORT TYPE AND DATES COVERED		
	December 2002	Annual (15 Nov	01 - 14 Nov 02)	
4. TITLE AND SUBTITLE			5. FUNDING NUMBERS	
Phase IIA Chemopreve	ntative Study of S	Selenium in	DAMD17-00-1-0062	
Persons at Risk for	Lung Cancer			
•	-			
6. AUTHOR(S) :				
Jeffrey P. Krischer,	Ph.D.			
7. PERFORMING ORGANIZATION NAM	ME(S) AND ADDRESS(ES)		8. PERFORMING ORGANIZATION	
			REPORT NUMBER	
University of South	Florida		·	
Tampa, Florida 3362	0-7900			
E-MAIL:		,		
jpkrischer@moffitt.usf.edu #				
9. SPONSORING / MONITORING AGE	NCV NAME(S) AND ADDRESS(ES	3	10. SPONSORING / MONITORING	
5. SPONSORING / WONTONING AGE	INC T NAME (S) AND ADDRESS(ES	''	AGENCY REPORT NUMBER	
U.S. Army Medical Research and M	lateriel Command			
Fort Detrick, Maryland 21702-5012				
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY S			12b. DISTRIBUTION C	ODE
Approved for Public Rele	ase; Distribution Unl	imited		
	•			
12 ABSTDACT /Maximum 200 Words				

Selenized yeast has also recently been shown to reduce lung cancer incidence and mortality in a population of skin cancer patients. Smokers and survivors of early stage lung and head and neck cancers have had a long period of promotion by carcinogenic agents on the bronchial epithelium resulting in morphologic and molecular alterations. We hypothesize that these morphologic and molecular alterations can be detected and modulated by chemopreventive agents. We have proposed a Phase IIa chemoprevention trial evaluating five different dose levels of selenium administered daily for 3 months in subjects at high risk for lung cancer with bronchoscopically documented dysplasia. Subjects will be entered to determine the effect of dose on the modulation of biomarkers in response to selenium supplementation as well as to measure selenium levels and modulation of glutathione peroxidase as a measure of drug effect. In addition to morphology, the surrogate endpoint biomarkers to be examined include apoptosis, p53 expression, K-ras mutation analysis, p16 methylation, and upregulation of hnRNP A2/B1. Successful completion of this study will support selenium supplementation as potentially beneficial therapy in preventing the progression of lung carcinogenesis as well as identify surrogate endpoint markers that appear to be modulated by selenium supplementation.

14. SUBJECT TERMS:			15. NUMBER OF PAGES
Phase IIa Chemoprevent	17		
Lung Cancer	16. PRICE CODE		
17. SECURITY CLASSIFICATION	18. SECURITY CLASSIFICATION	19. SECURITY CLASSIFICATION	20. LIMITATION OF ABSTRACT
OF REPORT	OF THIS PAGE	OF ABSTRACT	
Unclassified	Unclassified	Unclassified	Unlimited

# **Table of Contents**

Cover1
SF 2982
Introduction4
Body 4-8
Key Research Accomplishments8
Reportable Outcomes8
Conclusions9
References9
Appendices
A. Figure Legends10
B. Fig. 1 - Histopathology Frequency in Current and Former Smokers11
C. Fig 2 - Bronchial Histopathology Findings by White Light Bronchoscopy12
D. Fig. 3 - Bronchial Histopathology Findings by Fluorescent Bronchoscopy13
E. Fig 4 - Percent Coded as Dysplasia14
F. Fig. 5 - Agreement Between Observations with White Light and LIFE Bronchoscopy15
G. Fig 6 - Hemoglobin Levels16
H. Fig 7 - Glutathione Peroxidase Activity17

# PHASE IIA CHEMOPREVENTION STUDY OF SELENIUM IN PERSONS AT RISK FOR LUNG CANCER

#### INTRODUCTION

Much knowledge has been acquired about the multi-step process of carcinogenesis in the lung during the last 20 years. Tumorigenesis appears to be the result of a number of genetic insults, although it remains to be determined whether there is a necessary sequence or a critical number of events required. Certain genetic alterations can be detected in the bronchial epithelium of persons at increased risk for lung cancer. Selenium may act through several different mechanisms of action, including stimulation of apoptosis, protection of tissue against oxidative damage, inhibition of tumor growth, reduction of mutagenic activity and reduction of activation of carcinogens and stimulation of the immune system. Selenized yeast has also recently been shown to reduce lung cancer incidence and mortality in a population of skin cancer patients. Smokers and survivors of early stage lung and head and neck cancers have had a long period of promotion by carcinogenic agents on the bronchial epithelium resulting in morphologic and molecular alterations. We hypothesize that these morphologic and molecular alterations can be detected and modulated by chemopreventive agents. We have proposed a Phase IIa chemoprevention trial evaluating five different dose levels of selenium administered daily for 3 months in subjects at high risk for lung cancer with bronchoscopically documented dysplasia. After establishing the maximum tolerated dose, additional subjects will be entered at that dose level in order to examine the modulation of biomarkers in response to selenium supplementation as well as to measure selenium levels and modulation of glutathione peroxidase as a measure of drug effect. In addition to morphology, the surrogate endpoint biomarkers to be examined include apoptosis, p53 expression, K-ras mutation analysis, p16 methylation, and upregulation of hnRNP A2/B1. Successful completion of this study will support selenium supplementation as potentially beneficial therapy in preventing the progression of lung carcinogenesis as well as identify surrogate endpoint markers that appear to be modulated by selenium supplementation.

#### **BODY**

The Statement of Work was submitted as a timeline. No secondary patient accrual was begun, and all patient accrual for completion of the initial accrual was stopped.

A total of 499 subjects have been screened for the study, with 153 eligible for the study. Of those eligible, 151 chose to participate in the study and sputum induction was performed. Forty-one were normal and 102 showed some abnormality, with 8 specimens showing inadequate levels of cells or no specimen could be produced. Fifty-three of those 102 subjects elected to continue on to the bronchoscopy. Analysis of bronchial biopsies resulted in 14 subjects being eligible to take part in the selenium dose selection phase of the study and all agreed to participate. All fourteen subjects have completed three months of selenium at the five dose levels.

# **Demographics**

Of the 151 subjects who had a sputum induction, 96 were male and 55 female. The group consisted of 90 current smokers and 61 former smokers. Of the 53 subjects who proceeded to bronchoscopy, 41 were male and 12 were female. This group consisted of 23 current and 30 former smokers. Mean pack-years of smoking were 61.2 for males, 58.1 for females, 51.8 for former smokers and 72.4 for current smokers.

# Sputum results

Sputum inductions on 151 subjects produced the following results:

Sputum Cytology Results	Number
No Significant Abnormality	41
Metaplasia	82
Mild Dysplasia	17
Moderate Dysplasia	2
Severe Dysplasia	1
Insufficient material/Not interpretable	8

The 102 subjects with metaplasia or dysplasia were eligible to proceed to bronchoscopy.

# **Bronchoscopy Results**

Bronchoscopy was performed on 53 individuals. Those with dysplasia qualified to enter for selenium dose supplementation. Fourteen individuals were randomly assigned to one of five dose levels of selenium for 3 months and had a second bronchoscopy upon completion. The bronchoscopy results were as follows:

Bronchial Histopathology	Initial	3 Month
No Significant Abnormality	14	0
Basal Cell Hyperplasia	0	1
Regular Metaplasia	23	1
Mild dysplasia	11	8
Moderate Dysplasia	4	3
Severe Dysplasia	1	1
CIS	0	0
Invasive Cancer	0	0
Total	53	14

Data is presented by smoking status, atypia, and bronchoscopy findings in figures 1-3.

## Selenium Blood Levels

Blood samples taken from 14 selenium participants at baseline and at 3 months show increases in blood selenium levels for all subjects. Average selenium level at baseline was 130

mcg/l and at 3 months was 305.5 mcg/l. The selenium levels for those who did not proceed with the study was 131.7 mcg/l. None of the baseline levels of selenium suggest a dietary deficiency.

#### **Adverse Events**

A total of eight adverse event reports were filed, none of which were determined to be study related. Two adverse event reported for study subject number 146 were thought to be an outcome of either anesthesia or dehydration from fasting for the bronchoscopy. A summary of the events is shown below.

Patient ID	Date of Event	Event	Study Related	Outcome
003	5/01/98	Asthma	No	Resolved
010	8/18/98	Cough, chest tightness, fever	No	Resolved
010	8/25/98	Follow-up	No	Resolved
074	12/17/98	Vaso-vagal response, post bronchoscopy	Possibly	Resolved
014	1/10/99	Hernia	No	Herniorrhaphy
014	2/01/99	Fever	No	Resolved
146	12/3/99 to 12/5/99	Migraine headache	Possibly	Resolved
146	8/6/99 to 8/9/99	Migraine headache	Possibly	Resolved

No selenium dependent toxicity was reported for any dose level.

# **Laboratory Progress Report**

For the 14 individuals who have completed the study:

- 140 biopsies have been formalin fixed and paraffin embedded, with most already sectioned in preparation for use.
- 72 biopsy samples have been micro-dissected for collection of atypical and normal cells from the same site.
- 28 blood samples, with GPX assays done in triplicate including control assays for no substrate, no sample and a positive control with purified GPX (Figure 7) as well as hemoglobin levels (Figure 6).
- Methylation specific PCR (MSP) of the p16 gene has been done on both the baseline and post-selenium sputum samples. No aberrant methylation patterns have been detected.
- MSP has been done on DNA extracted from bronchial cells collected at the biopsy site but failed to attach to the culture dishes. To date, 192 samples have been tested for MSP of the p16 gene. Using control primers, 158 of the samples could be analyzed (82.3%) but only one sample showed a positive result for MSP of the p16 gene (0.52%).
- All bronchial biopsy specimens for both the baseline and 3 month samples were immunostained for altered p16 expression. No obvious change in the staining pattern was seen between the two samples at the same biopsy site for the same individual. We are awaiting evaluation of the staining by a trained pathologist.

- Assays for the detection of K-ras mutation in codon 12 proved unreliable and were discontinued.
- An assay was developed for the detection of over-expression of the p53 protein using standard immunohistochemistry on sputum samples. Sputum samples for the fourteen individuals who have completed the study were tested. The samples have been stained and await interpretation by a cytopathologist.
- A standard TUNEL assay was used to detect apoptosis in the bronchial biopsies. No apoptotic cells were detected in any of the samples although all controls performed well.
- Proliferation assay based on immunostaining for Ki-67 were tested and discarded because
  of unreliable positive control. Proliferation assay based on immunohistochemical staining
  for the Proliferation Cell Nuclear Antigen (PCNA) was substituted. No difference in
  staining intensity or location of stain for PCNA was detected between the baseline and 3month biopsy specimens from the same individual but we have submitted the samples to a
  pathologist for interpretation.
- A subset of the biopsy samples were evaluated with an antibody directed against GADD 153, one of the proteins involved growth arrest in cells. No obvious difference was detected between biopsies collected before and after selenium supplementation, but we have submitted the samples to a pathologist for interpretation.
- A subset of the biopsy samples were evaluated with an antibody directed against p27, a cyclin dependent kinase inhibitor. No obvious difference was detected between biopsies collected before and after selenium supplementation, but we have submitted the samples to a pathologist for interpretation.
- A subset of the biopsy samples were evaluated with an antibody directed against FasL, part of the initial signaling for an apoptosis cascade. No obvious difference was detected between biopsies collected before and after selenium supplementation, but we have submitted the samples to a pathologist for interpretation.
- A subset of the biopsy samples were evaluated with two different antibodies directed against thioredoxin reductase, a selenium containing enzyme. No obvious difference was detected between biopsies collected before and after selenium supplementation, but we have submitted the samples to a pathologist for interpretation.

# For all study subjects

- Tissue culture of normal bronchial epithelial cells on 53 study subjects
- 283 NHBE cultures have been attempted with 139 growing well enough for the collection of cells for the preparation of DNA or stored for regrowth.
- DNA has been prepared from either the cells grown in culture or from cells that failed to attach to the culture dish.
- 53 blood samples processed for isolation of lymphocytes and for the baseline measurement of GPX plus 14 additional samples from individuals who completed selenium supplementation (Figure 7).
- All samples, whole blood and lymphocytes, are stored at -80°C. All NHBE cultures are stored in liquid nitrogen.
- All biopsy blocks were stored and controlled by the Pathology Department of the H. Lee Moffitt Cancer Center. In general, for most study subjects the number of biopsies is the same as the number of sites used for collecting NHBE for cell culture. For a few study subjects, extra biopsies were taken at the discretion of the physician. To facilitate

- development of immunoassays, all biopsy blocks were cut to completion. All sections are currently stored in the Cancer Prevention Laboratory.
- Comparison of the interpretation of the pathology findings by our study pathologist (Dr. Khoor) with those of a blinded consultant (Dr. Gazdar) has been completed. No significant difference was found (Figure 4).

## KEY RESEARCH ACCOMPLISHMENTS

- Established feasibility of recruiting and enrolling heavy current and former smokers on a chemoprevention study
- Developed algorithm to recruit and screen subjects, obtain induced sputum specimens, obtain history and physical and screening chest x-ray and blood work prior to bronchoscopy, obtain bronchoscopy and start eligible subjects on selenium supplement.
- Developed close collaborative relationships with pulmonary medicine and pathology
- Evaluated induced sputa from high risk individuals for p16 hypermethylation (all with no hypermethylation detected)
- Developed archive of 274 bronchial epithelial cell cultures
- Developed archive of induced sputum specimens from 151 high risk individuals
- Evaluated the value of fluorescent bronchoscopy in addition to white light bronchoscopy in predicting dysplasia in a high risk population (Figure 5).
- Measured glutathione peroxidase pre- and post-selenium supplementation and found no change
- Measured selenium pre- and post-selenium supplementation and found increase (dose still blinded)

# REPORTABLE OUTCOMES

- Development of repository of induced sputum specimens from 151 individuals
- Development of repository of bronchial epithelial cell cultures (274 cultures from 53 study subjects).
- Serum and lymphocyte repository from the same patient population.
- Fluorescent light bronchoscopy better predicts atypia than white light bronchoscopy (Figure 5).
- No p16 hypermethylation was detected in DNA samples from sputum collected at baseline for the 14 individuals who received selenium supplementation nor could we detect changes in the protein levels in biopsy specimens by immunostaining for p16.
- NHBE cells cultured in the laboratory were tested for the presence of hypermethylation of the p16 promoter region. From a total of 192 cultures tested for hypermethylation of the p16 promoter, we found that 158 cultures could be amplified (82.3%) with only one culture positive (0.52%).

## **CONCLUSIONS**

The dose levels of selenium used in the initial phase of the protocol appears to have no obvious toxicity. We assume that at least two individuals have received the highest dose of selenium (1000  $\mu$ g). The blood selenium levels increased after supplementation with selenomethionine. Baseline levels range from 92-200  $\mu$ g/l and the levels after supplementation range from 190-460  $\mu$ g/l. Once we unblind the study, we will be able to determine which doses are most effective at increasing the blood selenium levels.

Based on our current analysis, fluorescent bronchoscopy is better able to detect atypia than white light bronchoscopy. This analysis confirms the initial anecdotal comments we were receiving from the bronchoscopy physicians and personnel.

Analysis of the hypermethylation of the p16 promoter region has, so far, not shown any significant alteration of the region to suggest repression of transcription. We failed to detect a methylation specific PCR product in either sputum samples or in cells collected from the biopsy site. The samples we used to prepare DNA may have contained insufficient atypical cells for detection of an altered gene. We have completed immunostaining biopsy specimens for the expression of p16 protein and have not seen a difference in the expression between the baseline and 3 month biopsy samples from the same individual.

Glutathione peroxidase activity is not an adequate marker for measuring different levels of selenium. None of the samples collected after selenium supplementation showed a significant change in activity which would result from increased selenium in the blood. Even though we do not know the dose level for the different study subjects, we do know the blood levels. Apparently, the normal baseline levels of selenium are sufficient for optimal enzyme activity.

The lack of any reportable selenium dependent biomarker modulation suggests that the optimal dose level for a selenium chemoprevention trial is not able to be set. After hearing a presentation on this study in November, 1999, the external scientific advisor committee, recommended finishing the current trial for the planned study period (Phase I), but not initiating another trial (the Phase II portion) unless a better rationale and a more focused approach was developed. With the aid of an unblinded statistician and the interpretations of our pathologist, we will now evaluated the effect supplementation at different selenium doses on the biomarker panel.

# REFERENCES

1. Berggren, M., Gallegos, A., Gasdaska, J. and Powis, G. 1997. Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Research 17:3377-3380.

## **APPENDICES**


Figure legend and Figures 1-7.

#### **APPENDIX**


# Figure Legends

- Figure 1: Histopathology diagnosis correlated with smoking status. Multiple biopsies were taken for each individual. The frequency of the most severe bronchial histopathology is correlated with the smoking status obtained from the enrollment questionare.
- Figure 2: Histopathology diagnosis correlated with the observed white light bronchoscopy. Multiple biopsies were taken for each individual and each biopsy has both the histopathology diagnosis as well as the interpretation by white light (White light classification is: Class I is normal; Class II is characterized by inflammation and/or metaplasia to mild atypia; Class III is characterized by moderate to severe atypia).
- Figure 3: Histopathology diagnosis correlated with the observed fluorescent light bronchoscopy. Multiple biopsies were taken for each individual and each biopsy has both the histopathology diagnosis as well as the interpretation by white light (Fluorescent light classification is: Class I is normal; Class II is characterized by inflammation and/or metaplasia to mild atypia; Class III is characterized by moderate to severe atypia).
- Figure 4: A consulting pathologist was recruited to validated the diagnosis of our study pathologist. The results show the percent of dysplasia diagnosed in both the biopsies (Path Findings) and in the overall diagnosis (Path Diagnosis).
- Figure 5: A comparison of the atypia described during both the white light and fluorescent LIFE bronchoscopy shows that LIFE calls more severe atypia than white light. This is supported by LIFE showing a stronger correlation to the histopathological diagnosis than white light.
- Figure 6: Hemoglobin measurements at baseline and after 3 months of selenomethionine supplementation. Total hemoglobin was measured from lysed red blood cells using a kit purchased from Sigma Diagnostics (Cat. No. 525-A). The procedure is based on the oxidation of hemoglobin to methemoglobin and the subsequent conversion of methemoglobin to cyanmethemoglobin by potassium cyanide which has a maximum adsorption at 540 nm. The color intensity measured at 540 nm is proportional to the total hemoglobin concentration. Note that hemoglobin values measured in this way are higher than those obtained with other clinical chemistries.
- Figure 7: Glutathione peroxidase activity per gram hemoglobin in blood samples taken at baseline and after 3 months of selenomethionine supplementation. Glutathione peroxidase (GPX) activity assay was done in triplicate for each blood sample collected at baseline and after 3 months of selonomethionine supplementation. A separate assay with purified GPX was done as a positive control and assays without sample or the organic peroxide substrate were done as negative controls. The assay is an indirect measure of GPX activity where oxidized glutathione is produced upon reduction of organic peroxide (*tert*-butyl hydroperoxide) and is recycled to its reduced state by exogenously added glutathione reductase (GR). The reduction of oxidized glutathione by GR requires the oxidation of NADPH. The GPX activity is determined by a decrease in adsorption at 340 nm as NADPH is oxidized to NADP. Using the molar extinction coefficent for NADPH (6220 M<sup>-1</sup>cm<sup>-1</sup>) and the rate of decrease in absorbance at 340 nm, the GPX activity for each sample can be calculated.


Histopathology Frequency in Current and Former Smokers



Bronchial Histopathology Findings by White Light Bronchoscopy



Bronchial Histopathology Findings by Fluorescent Light Bronchoscopy Figure 3






Figure 5: Agreement Between Observations with White Light and LIFE Bronchoscopy


LIFE CLASS

		1	II	III
WHITE	l	156	81	5
LIGHT		13	15	2
CLASS	III	2	0	2

Observations by LIFE bronchoscopy of 276 endobronchial sites correlated with those by white light bronchoscopy (Spearman correlation coefficient R=0.16, p=0.0087). Agreement was not strong with Kappa statistic=0.108 (95% confidence limits 0.014, 0.20).

Histopathological diagnosis showed a better correlation with LIFE bronchoscopy (R=0.12, p=0.053) than with white light bronchoscopy (R=-0.075, p=0.233).

Hemoglobin Levels Figure 6



- Baseline GPX Activity --- 3 Month GPX Activity Samples 20 1 à <del>1</del> 우 GPX Activity (Units/g Hg)

**Glutathione Peroxidase Activity** 

Figure 7